Growth Metrics

Pfizer (PFE) Current Taxes (2016 - 2026)

Pfizer has reported Current Taxes over the past 18 years, most recently at $3.1 billion for Q1 2026.

  • Quarterly Current Taxes rose 0.81% to $3.1 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.1 billion through Mar 2026, up 0.81% year-over-year, with the annual reading at $3.1 billion for FY2025, 6.63% up from the prior year.
  • Current Taxes was $3.1 billion for Q1 2026 at Pfizer, up from $3.1 billion in the prior quarter.
  • Over five years, Current Taxes peaked at $3.8 billion in Q3 2025 and troughed at $1.6 billion in Q4 2022.
  • The 5-year median for Current Taxes is $3.1 billion (2022), against an average of $2.9 billion.
  • Year-over-year, Current Taxes skyrocketed 126.77% in 2022 and then crashed 38.2% in 2023.
  • A 5-year view of Current Taxes shows it stood at $1.6 billion in 2022, then skyrocketed by 48.02% to $2.3 billion in 2023, then rose by 23.88% to $2.9 billion in 2024, then increased by 6.63% to $3.1 billion in 2025, then rose by 0.87% to $3.1 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Current Taxes are $3.1 billion (Q1 2026), $3.1 billion (Q4 2025), and $3.8 billion (Q3 2025).